<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33762624</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Mar</Month><Day>24</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Poliovirus-nonsusceptible Vero cell line for the World Health Organization global action plan.</ArticleTitle><Pagination><StartPage>6746</StartPage><MedlinePgn>6746</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">6746</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-86050-3</ELocationID><Abstract><AbstractText>Polio or poliomyelitis is a disabling and life-threatening disease caused by poliovirus (PV). As a consequence of global polio vaccination efforts, wild PV serotypes 2 and 3 have been eradicated around the world, and wild PV serotype 1-transmitted cases have been largely eliminated except for limited regions. However, vaccine-derived PV, pathogenically reverted live PV vaccine strains, has become a serious issue. For the global eradication of polio, the World Health Organization is conducting the third edition of the Global Action Plan, which is requesting stringent control of potentially PV-infected materials. To facilitate the mission, we generated a PV-nonsusceptible Vero cell subline, which may serve as an ideal replacement of standard Vero cells to isolate emerging/re-emerging viruses without the risk of generating PV-infected materials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Okemoto-Nakamura</LastName><ForeName>Yuko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-9640, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Someya</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Virology 3 and WHO Global Specialized Laboratory for Measles and Rubella, National Institute of Infectious Diseases, 4-7-1, Gakuen, Musashimurayama, Tokyo, 208-0011, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamaji</LastName><ForeName>Toshiyuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-9640, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Kyoko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-9640, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeda</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Virology 3 and WHO Global Specialized Laboratory for Measles and Rubella, National Institute of Infectious Diseases, 4-7-1, Gakuen, Musashimurayama, Tokyo, 208-0011, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanada</LastName><ForeName>Kentaro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-9640, Japan. hanak@nih.go.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011991">Receptors, Virus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018929" MajorTopicYN="N">Cell Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011991" MajorTopicYN="N">Receptors, Virus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056189" MajorTopicYN="Y">Viral Tropism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014944" MajorTopicYN="N">World Health Organization</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33762624</ArticleId><ArticleId IdType="pmc">PMC7991635</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-86050-3</ArticleId><ArticleId IdType="pii">10.1038/s41598-021-86050-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nomoto A, Koike S, Aoki J. Tissue tropism and species specificity of poliovirus infection. Trends Microbiol. 1994;2:47&#x2013;51. doi: 10.1016/0966-842x(94)90125-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0966-842x(94)90125-2</ArticleId><ArticleId IdType="pubmed">8162441</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonge O. What can over 30 years of efforts to eradicate polio teach us about global health? BMC Public Health. 2020;20(2):1177. doi: 10.1186/s12889-020-09198-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-020-09198-z</ArticleId><ArticleId IdType="pmc">PMC7419726</ArticleId><ArticleId IdType="pubmed">32787897</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaghaghi M, et al. New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data. Vaccine. 2018;36:1711&#x2013;1719. doi: 10.1016/j.vaccine.2018.02.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.02.059</ArticleId><ArticleId IdType="pubmed">29478755</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin GR, et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science. 2020;368:401&#x2013;405. doi: 10.1126/science.aba1238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aba1238</ArticleId><ArticleId IdType="pmc">PMC10805349</ArticleId><ArticleId IdType="pubmed">32193361</ArticleId></ArticleIdList></Reference><Reference><Citation>The World Health Organization . WHO Global Action Plan to Minimize Poliovirus Facility-Associated Risk After Type-Specific Eradication of Wild Polioviruses and Sequential Cessation of Oral Polio Vaccine Use. Cleveland: WHO Press; 2015.</Citation></Reference><Reference><Citation>Yasumura, Y. &amp; Kawakita, Y. in VERO Cells: Origin, Properties and Biomedical Applications (eds Simizu B. &amp; T. Terasima) 1&#x2013;19 (Department of Microbiology School of Medicine Chiba University, 1988).</Citation></Reference><Reference><Citation>Osada N, et al. The genome landscape of the African green monkey kidney-derived Vero cell line. DNA Res. 2014;21:673&#x2013;683. doi: 10.1093/dnares/dsu029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/dnares/dsu029</ArticleId><ArticleId IdType="pmc">PMC4263300</ArticleId><ArticleId IdType="pubmed">25267831</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakuma C, et al. Novel endogenous simian retroviral integrations in Vero cells: implications for quality control of a human vaccine cell substrate. Sci. Rep. 2018;8:644. doi: 10.1038/s41598-017-18934-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-18934-2</ArticleId><ArticleId IdType="pmc">PMC5766633</ArticleId><ArticleId IdType="pubmed">29330501</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuel CE. Antiviral actions of interferons. Clin. Microbiol. Rev. 2001;14:778&#x2013;809. doi: 10.1128/CMR.14.4.778-809.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.14.4.778-809.2001</ArticleId><ArticleId IdType="pmc">PMC89003</ArticleId><ArticleId IdType="pubmed">11585785</ArticleId></ArticleIdList></Reference><Reference><Citation>Falzarano D, et al. Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin. Sci. Rep. 2013;3:1686. doi: 10.1038/srep01686.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep01686</ArticleId><ArticleId IdType="pmc">PMC3629412</ArticleId><ArticleId IdType="pubmed">23594967</ArticleId></ArticleIdList></Reference><Reference><Citation>Pires de Mello CP, Drusano GL, Rodriquez JL, Kaushik A, Brown AN. Antiviral effects of clinically-relevant interferon-alpha and ribavirin regimens against dengue virus in the hollow fiber infection model (HFIM) Viruses. 2018 doi: 10.3390/v10060317.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v10060317</ArticleId><ArticleId IdType="pmc">PMC6024321</ArticleId><ArticleId IdType="pubmed">29890736</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis DS, et al. Ebola and Marburg viruses: II. Thier development within Vero cells and the extra-cellular formation of branched and torus forms. J. Med. Virol. 1979;4:213&#x2013;225. doi: 10.1002/jmv.1890040307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.1890040307</ArticleId><ArticleId IdType="pubmed">119829</ArticleId></ArticleIdList></Reference><Reference><Citation>Ksiazek TG, et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 2003;348:1953&#x2013;1966. doi: 10.1056/NEJMoa030781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa030781</ArticleId><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference><Reference><Citation>Drosten C, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 2003;348:1967&#x2013;1976. doi: 10.1056/NEJMoa030747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa030747</ArticleId><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuyama S, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl. Acad. Sci. U.S.A. 2020;117:7001&#x2013;7003. doi: 10.1073/pnas.2002589117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2002589117</ArticleId><ArticleId IdType="pmc">PMC7132130</ArticleId><ArticleId IdType="pubmed">32165541</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 2012;367:1814&#x2013;1820. doi: 10.1056/NEJMoa1211721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211721</ArticleId><ArticleId IdType="pubmed">23075143</ArticleId></ArticleIdList></Reference><Reference><Citation>Montagnon BJ, Vincent-Falquet JC. Experience with the Vero cell line. Dev. Biol. Stand. 1998;93:119&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">9737386</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett PN, Mundt W, Kistner O, Howard MK. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev. Vaccines. 2009;8:607&#x2013;618. doi: 10.1586/erv.09.19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.09.19</ArticleId><ArticleId IdType="pubmed">19397417</ArticleId></ArticleIdList></Reference><Reference><Citation>Montomoli E, et al. Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production. Expert Rev. Vaccines. 2012;11:587&#x2013;594. doi: 10.1586/erv.12.24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.12.24</ArticleId><ArticleId IdType="pubmed">22827244</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren WC, et al. The genome of the vervet (Chlorocebus aethiops sabaeus) Genome Res. 2015;25:1921&#x2013;1933. doi: 10.1101/gr.192922.115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.192922.115</ArticleId><ArticleId IdType="pmc">PMC4665013</ArticleId><ArticleId IdType="pubmed">26377836</ArticleId></ArticleIdList></Reference><Reference><Citation>Koike S, et al. A second gene for the African green monkey poliovirus receptor that has no putative N-glycosylation site in the functional N-terminal immunoglobulin-like domain. J. Virol. 1992;66:7059&#x2013;7066. doi: 10.1128/JVI.66.12.7059-7066.1992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.66.12.7059-7066.1992</ArticleId><ArticleId IdType="pmc">PMC240372</ArticleId><ArticleId IdType="pubmed">1331508</ArticleId></ArticleIdList></Reference><Reference><Citation>Koike S, et al. Transgenic mice susceptible to poliovirus. Proc. Natl. Acad. Sci. U.S.A. 1991;88:951&#x2013;955. doi: 10.1073/pnas.88.3.951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.88.3.951</ArticleId><ArticleId IdType="pmc">PMC50932</ArticleId><ArticleId IdType="pubmed">1846972</ArticleId></ArticleIdList></Reference><Reference><Citation>Koike S. The risk of unintentional propagation of poliovirus can be minimized by using human cell lines lacking the functional CD155 gene. Microbiol. Immunol. 2020;64:835&#x2013;839. doi: 10.1111/1348-0421.12843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1348-0421.12843</ArticleId><ArticleId IdType="pubmed">32902876</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa M, et al. Molecular mechanisms of Streptococcus pneumoniae-targeted autophagy via pneumolysin, Golgi-resident Rab41, and Nedd4-1-mediated K63-linked ubiquitination. Cell. Microbiol. 2018;20:e12846. doi: 10.1111/cmi.12846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cmi.12846</ArticleId><ArticleId IdType="pubmed">29582580</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaji T, et al. A CRISPR screen identifies LAPTM4A and TM9SF proteins as glycolipid-regulating factors. iScience. 2019;11:409&#x2013;424. doi: 10.1016/j.isci.2018.12.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2018.12.039</ArticleId><ArticleId IdType="pmc">PMC6348303</ArticleId><ArticleId IdType="pubmed">30660999</ArticleId></ArticleIdList></Reference><Reference><Citation>Manukyan H, et al. Quantitative multiplex one-step RT-PCR assay for identification and quantitation of Sabin strains of poliovirus in clinical and environmental specimens. J. Virol. Methods. 2018;259:74&#x2013;80. doi: 10.1016/j.jviromet.2018.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2018.06.009</ArticleId><ArticleId IdType="pubmed">29920299</ArticleId></ArticleIdList></Reference><Reference><Citation>Manukyan H, et al. Multiplex PCR-based titration (MPBT) assay for determination of infectious titers of the three Sabin strains of live poliovirus vaccine. Virol. J. 2019;16:122. doi: 10.1186/s12985-019-1233-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-019-1233-6</ArticleId><ArticleId IdType="pmc">PMC6819588</ArticleId><ArticleId IdType="pubmed">31660997</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>